Children & Families
Expanding access to birth control is the surest way to defend women’s right to choose
The 2009 Conference on Clinical Cancer Research, hosted by the Engelberg Center for Health Care Reform and Friends of Cancer Research, brought together distinguished members of the cancer community for in-depth discussions of critical issues at the intersection of clinical research and policy.
The all-day event on September 14 convened leaders from the National Cancer Institute (NCI), academia, patient advocacy organizations, the Food and Drug Administration (FDA), and various industry organizations, to discuss specific research and policy issues, as well as build consensus around solutions to critical questions regarding the future of clinical cancer research.
Opening remarks were delivered by NCI Director John Niederhuber, with keynote remarks offered by FDA Commissioner Margaret Hamburg. Interactive panel discussions focused on optimal data collection for clinical trials, development and approval of targeted therapies, and development of combination therapies targeting multiple pathways.
Agenda
-
September 14
-
Welcome
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke UniversityJNJohn Niederhuber Director, National Cancer Institute -
Panel 1: Data Submission Standards and Evidence Requirements
RSRichard Schilsky Chief Medical Officer - American Society of Clinical OncologyJAJeffrey Abrams National Cancer InstituteRERobert Erwin Marti Nelson Cancer FoundationRTRobert Temple Deputy Director for Clinical Science, Center for Drug Evaluation and Research - U.S. Food and Drug Administration -
Panel 2: Blinded Independent Central Review of PFS Endpoints
MDSModerator: Daniel Sargent Mayo ClinicWBWill Bushnell GlaxoSmithKlineNRNancy Roach C3: Colorectal Cancer CoalitionRPRichard Padzur Food and Drug Administration -
Keynote Address
IESIntroduction: Ellen Sigal Friends of Cancer ResearchMHMargaret Hamburg Commissioner - U.S. Food and Drug Administration -
Panel 3: Accelerating Development and Approval of Targeted Cancer Therapies
ABAnna Barker National Cancer InstituteDEDavid Epstein NovartisCSFCo-Moderator: Stephen Friend President, Sage BionetworksCGCindy Geoghegan Patient and PartnersDSDavid Sidransky The Johns Hopkins University School of MedicineRWRaymond Woosley Critical Path InstitutePKPatricia Keegan Food and Drug Administration -
Panel 4: Development of Two Novel Therapeutics Targeting Multiple Pathways
MCEModerator: Charles Erlichman Mayo ClinicACAdam Clark Director, Scientific and Federal Affairs, Faster CuresMEMatthew Ellis Washington University in St. LouisSLStuart Lutzker GenentechJZJames Zwiebel National Cancer InstituteJWJanet Woodcock Director, Center for Drug Evaluation and Research - US Food and Drug Administration -
Summary and Closing Remarks
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University
-
